- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Looking to the Future of AD Treatment
Author(s):
Brett King, MD, of Yale School of Medicine, discusses the future of atopic dermatitis treatment.
In this video, taken at the at the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference being held from April 9 to 11, in Baltimore, Maryland, Brett King, MD, of Yale School of Medicine, discusses the future of atopic dermatitis treatment, noting that the addition of targeted agents is enabling better responses in patients.
Video Player is loading.
Related Videos
Balancing Effective AD Symptom Control with Long-Term Safety in New Therapies
Key Considerations for Evaluating Ruxolitinib Cream as a Treatment for Young Children
Supporting Caregivers in Successful Long-Term Atopic Dermatitis Management: The Role of Dermatologists
Challenges and Emerging Solutions in Treatment for Age Groups: Addressing Disease Control, Safety, and Usability
Challenges and Unmet Needs in Treating Pediatric Atopic Dermatitis
New Biomarker Test Revolutionizes Inflammatory Skin Disease Diagnosis
Reviewing 3 Key Lebrikizumab Abstracts From AAD 2025
Future Directions for Pediatric Atopic Dermatitis Management and Research
New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors
Addressing Disparities in Inflammatory Skin Diseases in Darker Skin Tones
Related Content
